Loading...
Akari Therapeutics, Plc
AKTX•NASDAQ
HealthcareBiotechnology
$1.42
$0.16(12.69%)
Akari Therapeutics, Plc (AKTX) Stock Overview
Explore Akari Therapeutics, Plc’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-0.00
↓ 97.75%
EPS Growth
$-0.00
↑ 20.00%
Operating Margin
0.00%
↓ 28.78%
ROE
-956.20%
↓ 97.75%
Dividend Yield
0.00%
Analyst Recommendations data is not available for AKTXAnalyst Recommendations details for AKTX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
CEO
Mr. Abizer Gaslightwala
Employees
8
Headquarters
75/76 Wimpole Street, London
Founded
2014